Germany vs Solomon Islands: Prevalence rate of hypertension in adults aged 30-79
Germany
29.7
in 2019
Solomon Islands
29.8
in 2019
Germany rank
168th
Solomon Islands rank
166th
Prevalence rate of hypertension in adults aged 30-79 over time
- Germany
- Solomon Islands
How they compare
Solomon Islands currently reports 29.8 against 29.7 in Germany, a difference of 0.1.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Germany ahead.
Germany ranks 168th and Solomon Islands ranks 166th of 194 countries.
Germany has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Germany | Solomon Islands | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 44.43 | 23.89 | 20.54 | Germany |
| 2000s | 37.65 | 23.81 | 13.84 | Germany |
| 2010s | 32.05 | 27.53 | 4.52 | Germany |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in adults aged 30-79, Germany or Solomon Islands?
- Solomon Islands, at 29.8 against 29.7 in Germany as of 2019.
- What is the difference in prevalence rate of hypertension in adults aged 30-79 between Germany and Solomon Islands?
- 0.1, with Solomon Islands ahead.
- How many years of comparable data are there for Germany and Solomon Islands?
- 30 years are reported by both, from 1990 to 2019.
- How do Germany and Solomon Islands rank globally for prevalence rate of hypertension in adults aged 30-79?
- Germany ranks 168th and Solomon Islands ranks 166th of 194 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in adults aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of the population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.